(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 22.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.17%.
Spero Therapeutics's earnings in 2025 is -$69,763,000.On average, 1 Wall Street analyst forecast SPRO's earnings for 2025 to be -$79,952,217, with the lowest SPRO earnings forecast at -$79,952,217, and the highest SPRO earnings forecast at -$79,952,217.
In 2026, SPRO is forecast to generate -$64,297,237 in earnings, with the lowest earnings forecast at -$64,297,237 and the highest earnings forecast at -$64,297,237.